Основная статистика
| LEI | 549300GPK6FPJ3X8SZ39 |
| CIK | 1534120 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Avalo Therapeutics, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-37590 AVALO THERAPEUTICS, INC. |
|
| August 7, 2025 |
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates Exhibit 99.1 Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates •Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026 •Rita Jain, M.D. appointed to Board of Directors •Cash and short-term investments of approximately $113 million as of June 30, 2025 expected to provide runway into 2028 WAYNE, PA, August 7, 20 |
|
| June 20, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| June 20, 2025 |
ne mission. Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs. CORPORATE OVERVIEW JUNE 2025 | AVALO THERAPEUTICS, INC. (AVTX) Exhibit 99.1 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not histo |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| June 18, 2025 |
Avalo Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Plan. Exhibit 10.1 Avalo Therapeutics, Inc. Non-Employee Director Compensation Policy Amended Effective June 17, 2025 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Avalo Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation |
|
| June 18, 2025 |
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors Exhibit 99.1 Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors WAYNE, PA., June 18, 2025 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. “We are pleased to welcome Dr. Jain to Avalo’s Board of Directors,” s |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| June 5, 2025 |
, between Avalo Therapeutics, Inc. and Exhibit 1.1 AVALO THERAPEUTICS, INC. COMMON STOCK SALES AGREEMENT June 5, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Avalo Therapeutics, Inc. (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term |
|
| June 5, 2025 |
Up to $75,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-271225 PROSPECTUS SUPPLEMENT (To prospectus dated May 2, 2023) Up to $75,000,000 Common Stock We have entered into a sales agreement with TD Securities (USA) LLC (the “Agent”, or “TD Cowen”) dated June 5, 2025, relating to the sale of shares of our common stock, $0.001 par value per share, offered by this prospectus supplement. In accordance wi |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission F |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission F |
|
| June 4, 2025 |
avalocorporatepresentati June 2025 Corporate Presentation Avalo Therapeutics, Inc. |
|
| May 12, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Avalo Therapeutics, Inc. |
|
| May 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission F |
|
| May 12, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Avalo Therapeutics, Inc. |
|
| May 12, 2025 |
As filed with the Securities and Exchange Commission on May 12, 2025 As filed with the Securities and Exchange Commission on May 12, 2025 Registration Statement No. |
|
| May 12, 2025 |
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates Exhibit 99.1 Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates •Mike Heffernan appointed as Chairman of the Board •Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 •Cash on hand of approximately $125 million as of March 31, 2025 expected to provide runway into 2027, with optionality to extend into 2028 WAY |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-37590 AVALO THERAPEUTICS, INC. |
|
| May 12, 2025 |
As filed with the Securities and Exchange Commission on May 12, 2025 As filed with the Securities and Exchange Commission on May 12, 2025 Registration Statement No. |
|
| May 8, 2025 |
May 2025 Corporate Presentation Avalo Therapeutics, Inc. (AVTX) Exhibit 99.1 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward- looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are su |
|
| May 8, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission Fi |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy State |
|
| March 26, 2025 |
Avalo Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Plan. Exhibit 10.1 Avalo Therapeutics, Inc. Non-Employee Director Compensation Policy Amended Effective March 25, 2025 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Avalo Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation |
|
| March 26, 2025 |
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board Exhibit 99.1 Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board WAYNE, PA AND ROCKVILLE, MD, Mar. 26, 2025 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| March 20, 2025 |
Form of Director Indemnification Agreement. Exhibit 10.14 INDEMNIFICATION AGREEMENT This Indemnification Agreement, dated as of (this “Agreement”), is made by and between Avalo Therapeutics, Inc., a Delaware corporation (the “Company”) and (“Indemnitee”). RECITALS: A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B. Under Delaware law, a director or offic |
|
| March 20, 2025 |
Avalo Therapeutics, Inc. Incentive Compensation Clawback Policy, effective as of November 21, 2023. Exhibit 97.1 Incentive Compensation Clawback Policy Avalo Therapeutics, Inc. This policy supersedes all incentive compensation clawback policies previously adopted by the Avalo Therapeutics, Inc. Board of Directors 1. INTRODUCTION The Company’s Board of Directors (the “Board”) believes that it is in the best interests of the Company and its stockholders to create and maintain a culture that emphas |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37590 |
|
| March 20, 2025 |
List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Avalo Therapeutics, Inc. Entity Name Jurisdiction Medgenics Medical (Israel) Ltd. State of Israel Aevi Genomic Medicine Europe BVBA/SPRL Belgium AlmataBio, LLC Delaware |
|
| March 20, 2025 |
Avalo Reports 2024 Financial Results and Recent Business Updates Exhibit 99.1 Avalo Reports 2024 Financial Results and Recent Business Updates •Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 •Appointed Jennifer Riley as Chief Strategy Officer •Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, PA AND ROCKVILLE, MD, March 20, 202 |
|
| March 20, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| March 20, 2025 |
Exhibit 4.5 DESCRIPTION OF REGISTERED SECURITIES The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries. You should also refer to the amended and restated certificate of incorporation and the amended and restated bylaws, which are included as exhibits to this Annual Report on Form 10-K, an |
|
| March 20, 2025 |
Exhibit 19.1 AVALO THERAPEUTICS, INC. Insider Trading and Window Period Policy (as amended on May 15, 2018) I. Introduction This policy determines acceptable transactions in the securities of Avalo Therapeutics, Inc. (the “Company”) by our employees, directors and consultants. During the course of your employment, directorship or consultancy with the Company, you may receive important information |
|
| January 13, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissi |
|
| January 13, 2025 |
January 2025 Corporate Presentation Avalo Therapeutics, Inc. (AVTX) Exhibit 99.1 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward- looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that ar |
|
| January 2, 2025 |
Employment Agreement, dated November 21, 2024, by and between Avalo Therapeutics, Inc. and Exhibit 10.1 November 21, 2024 Jennifer Riley Dear Jen: On behalf of Avalo Therapeutics, Inc., a Delaware corporation (the “Company”), we are pleased to formalize for you the terms of your employment with the Company as set forth in this agreement (the “Agreement”). Please note that this offer of employment is contingent upon a clearance of a background check and two satisfactory professional refe |
|
| January 2, 2025 |
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer Exhibit 99.1 Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer WAYNE, PA AND ROCKVILLE, MD, January 2, 2025 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2025 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissio |
|
| December 5, 2024 |
December 2024 Corporate Presentation Avalo Therapeutics, Inc. (AVTX) Exhibit 99.1 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward- looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that a |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissi |
|
| November 14, 2024 |
AVTX / Avalo Therapeutics, Inc. / Allostery Investments LP Passive Investment SC 13G/A 1 avalo13ga1-11142024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Avalo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05338F306 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check |
|
| November 14, 2024 |
AVTX / Avalo Therapeutics, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13G Passive Investment SC 13G 1 ss4113290sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 AVALO THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05338F306 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| November 12, 2024 |
November 2024 Corporate Presentation Avalo Therapeutics, Inc. (AVTX) EXHIBIT 99.2 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward- looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that a |
|
| November 12, 2024 |
Exhibit 99.1 Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants •Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to $185 million •Cash runway expected into at least 2027 WAYNE, PA AND ROCKVILLE, MD, November 12, 2024 – Avalo Therapeutics, Inc |
|
| November 12, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commiss |
|
| November 7, 2024 |
AVTX / Avalo Therapeutics, Inc. / Crutcher Patrick J Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Avalo Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 05338F306 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| November 7, 2024 |
As filed with the Securities and Exchange Commission on November 7, 2024 As filed with the Securities and Exchange Commission on November 7, 2024 Registration Statement No. |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-37590 AVALO THERAPEUTICS, INC. |
|
| November 7, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Avalo Therapeutics, Inc. |
|
| November 7, 2024 |
EXHIBIT 10.4 Avalo Therapeutics, Inc. Non-Employee Director Compensation Policy Amended Effective July 1, 2024 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Avalo Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation P |
|
| November 7, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Avalo Therapeutics, Inc. |
|
| November 7, 2024 |
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates Exhibit 99.1 Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates •Dosed first patient in Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa (HS), with topline data expected in 2026 •Cash position of approximately $82 million as of September 30, 2024 with subsequent receipt of approximately $58 million of warrant exercise proceeds in 4Q 2024, pr |
|
| November 7, 2024 |
As filed with the Securities and Exchange Commission on November 7, 2024 As filed with the Securities and Exchange Commission on November 7, 2024 Registration Statement No. |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissi |
|
| October 8, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissio |
|
| October 8, 2024 |
October 2024 Corporate Presentation Avalo Therapeutics, Inc. (AVTX) EXHIBIT 99.2 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward- looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that ar |
|
| October 8, 2024 |
Exhibit 99.1 Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa •Global study in approximately 180 adults with hidradenitis suppurativa to assess the efficacy and safety of two dose regimens of AVTX-009 compared to placebo •Topline data expected in 2026 WAYNE, PA AND ROCKVILLE, MD, October 8, 2024 – Avalo Therapeutics, Inc. (Nasdaq: |
|
| October 7, 2024 |
AVTX / Avalo Therapeutics, Inc. / Ikarian Capital, LLC - SC 13G Passive Investment SC 13G 1 d722112dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AVALO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 05338F306 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropr |
|
| October 7, 2024 |
Joint Filing Agreement (filed herewith). EX-99.1 2 d722112dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT October 7, 2024 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or |
|
| September 9, 2024 |
avaloinvestordeckseptemb 1 Avalo Therapeutics, Inc. (AVTX) Corporate Presentation September 2024 Exhibit 99.1 2 This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward- looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties tha |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commiss |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commiss |
|
| August 23, 2024 |
EX-99.1 2 ex991to13g07422avtx082324.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated August 23, 2024 with respect to the Common Stock, $0.001 par value per share, of Avalo Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on beh |
|
| August 23, 2024 |
AVTX / Avalo Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Avalo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05338F306 (CUSIP Number) August 13, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| August 23, 2024 |
AVTX / Avalo Therapeutics, Inc. / Crutcher Patrick J Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 23, 2024 |
AVTX / Avalo Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Avalo Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 05338F306 (CUSIP Number) |
|
| August 14, 2024 |
Exhibit 10.1 AVALO THERAPEUTICS, INC. FOURTH AMENDED AND RESTATED 2016 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 6, 2024 APPROVED BY THE STOCKHOLDERS: AUGUST 13, 2024 1. GENERAL. (a) Purpose. The Plan, through the granting of Awards, is intended to help the Company secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissio |
|
| August 14, 2024 |
Exhibit 10.2 Avalo Therapeutics, Inc. Amended and Restated 2016 Employee Stock Purchase Plan Adopted by the Board of Directors: June 6, 2024 Approved by the Stockholders: August 13, 2024 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan pe |
|
| August 12, 2024 |
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates Exhibit 99.1 Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates •Expects to enroll first patient in Phase 2 LOTUS Trial of AVTX-009 in hidradenitis suppurativa in the second half of 2024 •Appointed Dr. Mittie Doyle as Chief Medical Officer and Paul Varki as Chief Legal Officer •Cash on hand of approximately $93.4 million as of June 30, 2024 with expected cash runway |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissio |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-37590 AVALO THERAPEUTICS, INC. |
|
| August 5, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279992 PROSPECTUS Up to 22,357,897 Shares of Common Stock Issuable Upon Conversion of Shares of Series C Non-Voting Convertible Preferred Stock Offered by Selling Stockholders 22,357.897 Shares of Series C Non-Voting Convertible Preferred Stock Offered by Selling Stockholders Up to 11,967,526 Shares of Common Stock Issuable Upon the Exercise of |
|
| August 1, 2024 |
540 Gaither Road, Suite 400 Rockville, Maryland 20850 540 Gaither Road, Suite 400 Rockville, Maryland 20850 August 1, 2024 VIA EDGAR Division of Corporation Finance U. |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| July 29, 2024 |
Wyrick Robbins Yates & Ponton LLP 4101 Lake Boone Trail, Suite 300 Raleigh, North Carolina 27607 Wyrick Robbins Yates & Ponton LLP 4101 Lake Boone Trail, Suite 300 Raleigh, North Carolina 27607 July 29, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 29, 2024 |
As filed with the Securities and Exchange Commission on July 29, 2024 As filed with the Securities and Exchange Commission on July 29, 2024 Registration Statement No. |
|
| July 16, 2024 |
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer Exhibit 99.1 Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer WAYNE, PA and ROCKVILLE, MD, July 16, 2024 – Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. “We are thrilled to have Mittie join and grow our leadership team at an exciting time as we prepare to initiate our Pha |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| July 16, 2024 |
, 2024, by and between Avalo Therapeutics, Inc. and Exhibit 10.1 June 1, 2024 Mittie Doyle, MD Dear Mittie: On behalf of Avala Therapeutics, Inc., a Delaware corporation (the "Company"), we are pleased to formalize for you the terms of your employment with the Company as set forth in this agreement (the "Agreement"). Please note that this offer of employment is contingent upon a clearance of a background check and two satisfactory professional refe |
|
| July 11, 2024 |
Wyrick Robbins Yates & Ponton LLP 4101 Lake Boone Trail, Suite 300 Raleigh, North Carolina 27607 Wyrick Robbins Yates & Ponton LLP 4101 Lake Boone Trail, Suite 300 Raleigh, North Carolina 27607 July 11, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 11, 2024 |
Wyrick Robbins Yates & Ponton LLP 4101 Lake Boone Trail, Suite 300 Raleigh, North Carolina 27607 Wyrick Robbins Yates & Ponton LLP 4101 Lake Boone Trail, Suite 300 Raleigh, North Carolina 27607 July 11, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 11, 2024 |
As filed with the Securities and Exchange Commission on July 11, 2024 As filed with the Securities and Exchange Commission on July 11, 2024 Registration Statement No. |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A (Amendment No. |
|
| July 9, 2024 |
Exhibit 99.1 Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa •Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa WAYNE, PA and ROCKVILLE, MD, July 9, 2024 – Avalo Therapeutics, |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission F |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy State |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| June 24, 2024 |
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer Exhibit 99.1 Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer WAYNE, PA and ROCKVILLE, MD, June 24, 2024 – Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Paul Varki has joined the Company as its Chief Legal Officer. “We are delighted to have Paul join and grow our leadership team at an exciting time at Avalo following our acquisition and private placement |
|
| June 24, 2024 |
Unaudited Pro Forma Condensed Combined Financial Information EXHIBIT 99.2 Unaudited Pro Forma Condensed Combined Financial Information On March 27, 2024 (the “Closing Date”), Avalo Therapeutics, Inc. (the “Parent” or “Avalo”) entered into a definitive merger agreement (the “Agreement”) with AlmataBio, Inc., (the “Company” or “Acquiree” or “AlmataBio”) and the Company became a wholly owned subsidiary of the Parent (the “Transaction” or “Merger”). Avalo’s acq |
|
| June 24, 2024 |
Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment to the Executive Employment Agreement (the "Amendment") is made and entered into as of May 10, 2024, by and between Avalo Therapeutics, Inc., a Delaware Corporation (the "Company"), and Paul Varki ("Executive"). WHEREAS, the Company and Executive entered into an Executive Employment Agreement dated May 6, 2024 (the "Agreement"); and WHE |
|
| June 24, 2024 |
Employment Agreement, dated May 6, 2024, by and between Avalo Therapeutics, Inc. and Paul Varki ( Exhibit 10.1 May 6, 2024 Paul Varki Dear Paul: On behalf of Avalo Therapeutics, Inc., a Delaware corporation (the “Company”), we are pleased to formalize for you the terms of your employment with the Company as set forth in this agreement (the “Agreement”). Please note that this offer of employment is contingent upon a clearance of a background check and two satisfactory professional references. 1 |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 2 to Form 8-K filed March 28, 2024 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| June 24, 2024 |
1 Avalo Therapeutics, Inc. (AVTX) Corporate Presentation June 2024 Exhibit 99.1 2 This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward- looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based |
|
| June 24, 2024 |
EXHIBIT 99.1 ALMATABIO, INC. INDEX TO FINANCIAL STATEMENTS Report of Independent Auditors 2 Balance Sheet as of December 31, 2023 4 Statement of Operations and Comprehensive Loss for the period from April 28, 2023 (date of inception) to December 31, 2023 5 Statement of Changes in Redeemable Preferred Stock and Stockholders’ Deficit for the period from April 28, 2023 (date of inception) to December |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: þ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| June 6, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Avalo Therapeutics, Inc. |
|
| June 6, 2024 |
As filed with the Securities and Exchange Commission on June 6, 2024 As filed with the Securities and Exchange Commission on June 6, 2024 Registration Statement No. |
|
| June 3, 2024 |
ALMATABIO, INC. INDEX TO FINANCIAL STATEMENTS EXHIBIT 99.1 ALMATABIO, INC. INDEX TO FINANCIAL STATEMENTS Report of Independent Auditors 2 Balance Sheet as of December 31, 2023 4 Statement of Operations and Comprehensive Loss for the period from April 28, 2023 (date of inception) to December 31, 2023 5 Statement of Changes in Redeemable Preferred Stock and Stockholders’ Equity for the period from April 28, 2023 (date of inception) to December |
|
| June 3, 2024 |
Unaudited Pro Forma Condensed Combined Financial Information EXHIBIT 99.2 Unaudited Pro Forma Condensed Combined Financial Information On March 27, 2024 (the “Closing Date”), Avalo Therapeutics, Inc. (the “Parent” or “Avalo”) entered into a definitive merger agreement (the “Agreement”) with AlmataBio, Inc., (the “Company” or “Acquiree” or “AlmataBio”) and the Company became a wholly owned subsidiary of the Parent (the “Transaction” or “Merger”). Avalo’s acq |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 to Form 8-K filed March 28, 2024 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission F |
|
| May 13, 2024 |
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates Exhibit 99.1 Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates •Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026 •Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 WAYNE, PA AND ROCKVILLE, MD, May 13, 2024 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced bus |
|
| May 13, 2024 |
Exhibit 10.2 LICENSE AGREEMENT by and between FLAME BIOSCIENCES, INC. and ELI LILLY and COMPANY CERTAIN INFORMATION IDENTIFIED WITH THE MARK “(***)” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AGREEMENT This License Agreement (the “Agreement”), is entered into as of November 25th, 2019 |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission F |
|
| May 13, 2024 |
, 2021, by and between Flame Biosciences LLC and Eli Lilly and Company. Exhibit 10.3 CERTAIN INFORMATION IDENTIFIED WITH THE MARK “(***)” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FIRST AMENDMENT TO LICENSE AGREEMENT between Flame Biosciences, Inc. and Eli Lilly and Company This First Amendment to the License Agreement (the “Amendment”) is dated February 2, 2021, |
|
| May 13, 2024 |
AVTX / Avalo Therapeutics, Inc. / Allostery Investments LP Passive Investment SC 13G 1 avalo13g-05132024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Avalo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05338F306 (CUSIP Number) May 1, 2024 (Date of Event which Requires Filing of this Statement) Check the appropr |
|
| May 13, 2024 |
Exhibit 10.1 CERTAIN INFORMATION IDENTIFIED WITH THE MARK “(***)” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of December 6, 2023 (the “Effective Date”), by and among AlmataBio, Inc., a Delaware corpora |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-37590 AVALO THERAPEUTICS, INC. |
|
| April 23, 2024 |
AVTX / Avalo Therapeutics, Inc. / Emerald Bioventures, LLC Passive Investment SC 13G 1 emerald13g.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Avalo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05338F306 (CUSIP Number) March 27, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| April 5, 2024 |
AVTX / Avalo Therapeutics, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37590 |
|
| March 29, 2024 |
Exhibit 3.2 AVALO THERAPEUTICS, INC. FIFTH AMENDED AND RESTATED BYLAWS ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be established and maintained at the office of Corporation Service Company, in the City of Wilmington, in the County of New Castle, in the State of Delaware, and said corporation, or other such person or entity as the Board of Directors may from time to |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| March 29, 2024 |
Avalo Reports 2023 Financial Results and Provides Business Updates Exhibit 99.1 Avalo Reports 2023 Financial Results and Provides Business Updates •Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024 •Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million •Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 202 |
|
| March 28, 2024 |
1 Avalo Therapeutics, Inc. (AVTX) Avalo Acquires Anti-IL-1β mAb and Announces up to $185M Private Placement March 2024 Exhibit 99.2 2 This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward- looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks |
|
| March 28, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 27, 2024, by and among Avalo Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and each Purchaser is exe |
|
| March 28, 2024 |
Exhibit 3.3 CERTIFICATE OF DESIGNATION OF SERIES E NON-VOTING PREFERRED STOCK OF AVALO THERAPEUTICS, INC. Pursuant to Section 151 of the Delaware General Corporation Law Avalo Therapeutics, Inc., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify that, in accordance with Sections 141( |
|
| March 28, 2024 |
Exhibit 3.2 CERTIFICATE OF DESIGNATION OF SERIES D NON-VOTING PREFERRED STOCK OF AVALO THERAPEUTICS, INC. Pursuant to Section 151 of the Delaware General Corporation Law Avalo Therapeutics, Inc., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify that, in accordance with Sections 141( |
|
| March 28, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of March [], 2024, by and among Avalo Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Pur |
|
| March 28, 2024 |
Exhibit 4.1 NEITHER THE SECURITIES REPRESENTED HEREBY NOR THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) IN COMPLIANCE WITH RULE 144 UNDER THE SECURITIES AC |
|
| March 28, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION by and among AVALO THERAPEUTICS INC., PROJECT ATHENS MERGER SUB, INC., SECOND PROJECT ATHENS MERGER SUB, LLC, ALMATABIO, INC., and THE SECURITYHOLDERS’ REPRESENTATIVE IDENTIFIED HEREIN Dated as of March 27, 2024 TABLE OF CONTENTS Page ARTICLE I - THE MERGERS 2 Section 1.02 Certificate of Designation 2 Section 1.02 The Merger 2 Section 1.0 |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| March 28, 2024 |
Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES C NON-VOTING CONVERTIBLE PREFERRED STOCK OF AVALO THERAPEUTICS, INC. Pursuant to Section 151 of the Delaware General Corporation Law Avalo Therapeutics, Inc., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify that, in accordance with S |
|
| March 28, 2024 |
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million Exhibit 99.1 Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million •Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. •Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026 •Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 m |
|
| February 14, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-0787exhibit99.htm JOING FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing a |
|
| February 14, 2024 |
AVTX / Avalo Therapeutics, Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm243309d33sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* AVALO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 05338F108 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the |
|
| February 14, 2024 |
SC 13G/A 1 p24-0787sc13ga.htm AVALO THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Avalo Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05338F306 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Avalo Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 05338F306 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2024 |
AVTX / Avalo Therapeutics, Inc. / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissi |
|
| December 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commiss |
|
| December 28, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED OF AVALO THERAPEUTICS, INC. The undersigned, for purposes of amending the Amended and Restated Certificate of Incorporation, as amended (the “Certificate”), of Avalo Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware |
|
| December 28, 2023 |
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split Exhibit 99.1 Avalo Therapeutics Announces 1-for-240 Reverse Stock Split WAYNE, PA and ROCKVILLE, MD, December 27, 2023 — Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a 1-for-240 reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on December 28, 2023. The Company’s common stock will trade on the Nasdaq Capital Market on a |
|
| December 20, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commiss |
|
| December 7, 2023 |
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split Exhibit 99.1 Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split •Annual Meeting has been adjourned until December 20, 2023 •Most stockholders can vote via proxyvote.com or by calling 1-800-690-6903. If you have any questions about how to vote, please call 1-800-607-0088 WAYNE, PA AND ROCKVILLE, MD, December 7, 2023 — Avalo Therapeutics, Inc. (Nasdaq: AVTX) encourages its stockholder |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissi |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commiss |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissi |
|
| November 9, 2023 |
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates Exhibit 99.1 Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates •Successfully eliminated $35 million debt paving the way for future growth and innovation •Divested AVTX-800 series for potential milestone payments of $45 million, fully focusing the pipeline on Avalo’s promising immunology assets •Disclosed improved cash of approximately $10.2 million as of September 30 |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-37590 AVALO THERAPEUTICS, INC. |
|
| October 31, 2023 |
Avalo Completes Divestiture of AVTX-800 Series Exhibit 99.1 Avalo Completes Divestiture of AVTX-800 Series WAYNE, PA AND ROCKVILLE, MD, October 31, 2023 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it has completed the divestiture of its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collectively, the 800 Series) to AUG Therapeutics, LLC (AUG). The Company p |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissi |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy State |
|
| October 17, 2023 |
Fourth Amended and Restated Bylaws of Avalo Therapeutics, Inc. Exhibit 3.1 AVALO THERAPEUTICS, INC. FOURTH AMENDED AND RESTATED BYLAWS ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be established and maintained at the office of Corporation Service Company, in the City of Wilmington, in the County of New Castle, in the State of Delaware, and said corporation, or other such person or entity as the Board of Directors may from time t |
|
| October 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissi |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: þ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissio |
|
| September 26, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commis |
|
| September 26, 2023 |
Exhibit 99.1 Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation WAYNE, PA AND ROCKVILLE, MD, September 26, 2023 — In a major achievement, Avalo Therapeutics (Nasdaq: AVTX) proudly announces the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance Corporation (Nasdaq: HRZN). This significant milestone not only si |
|
| September 26, 2023 |
Exhibit 10.1 September 22, 2023 VIA ELECTRONIC AND REGULAR MAIL Avalo Therapeutics, Inc. (f/k/a Cerecor Inc.) 540 Gaither Road, Suite 400 Rockville, MD 20850 Attn: Garry Neil, Chief Executive Officer Re: Avalo Therapeutics, Inc. (f/k/a Cerecor Inc.) Payoff Letter Dear Mr. Neil: Reference is hereby made to that certain (a) Venture Loan and Security Agreement dated as of June 4, 2021 (as amended fro |
|
| September 13, 2023 |
Exhibit 10.1 THIRD FORBEARANCE AGREEMENT This THIRD FORBEARANCE AGREEMENT (this “Agreement”) is made as of September 13, 2023, by and among (i) Avalo Therapeutics, Inc. (f/k/a Cerecor Inc.), a Delaware corporation (the “Borrower”), (ii) Horizon Credit II LLC, Horizon Funding Trust 2019-1, Horizon Funding I, LLC, and Powerscourt Investments XXV Trust, as lenders (collectively, the “Lenders”), and ( |
|
| September 13, 2023 |
Exhibit 10.2 FIRST AMENDMENT TO VENTURE LOAN AND SECURITY AGREEMENT This FIRST AMENDMENT TO VENTURE LOAN AND SECURITY AGREEMENT (this “Agreement”) is made as of September 13, 2023, by and among Avalo Therapeutics, Inc. (f/k/a Cerecor Inc.), a Delaware corporation (the “Borrower”), Horizon Credit II LLC, a Delaware limited liability company (“HCII”), as an assignee of Horizon Technology Finance Cor |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commis |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commis |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commis |
|
| September 12, 2023 |
Avalo Enters into Agreement to Divest AVTX-800 Series Exhibit 99.1 Avalo Enters into Agreement to Divest AVTX-800 Series WAYNE, PA AND ROCKVILLE, MD, September 12, 2023 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement (the Purchase Agreement) with AUG Therapeutics, LLC (AUG) to sell its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) |
|
| September 12, 2023 |
Exhibit 2.1 CERTAIN INFORMATION IDENTIFIED WITH THE MARK “(***)” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made as of September 11, 2023, by and between Avalo Therapeutics, Inc., a Delaware corporation (“Seller”), an |
|
| September 11, 2023 |
1 © Copyright 2023. Avalo Therapeutics. All rights reserved. FOR DISCUSSION PURPOSES ONLY Avalo Therapeutics, Inc. September 2023 Corporate Presentation (AVTX) Exhibit 99.1 2 © Copyright 2023. Avalo Therapeutics. All rights reserved. This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are stateme |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commis |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissio |
|
| August 14, 2023 |
Exhibit 10.1 SECOND FORBEARANCE AGREEMENT This SECOND FORBEARANCE AGREEMENT (this “Agreement”) is made as of August 14, 2023, by and among (i) Avalo Therapeutics, Inc. (f/k/a Cerecor Inc.), a Delaware corporation (the “Borrower”), (ii) Horizon Credit II LLC, Horizon Funding Trust 2019-1, Horizon Funding I, LLC, and Powerscourt Investments XXV Trust, as lenders (collectively, the “Lenders”), and (i |
|
| August 8, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| August 7, 2023 |
Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-271225 Amendment No. 1 dated August 7, 2023 To Prospectus Supplement dated May 4, 2023 (To Prospectus dated May 2, 2023) Up to $50,000,000 Common Stock This Amendment No. 1 to Prospectus (the “Amended Prospectus Supplement”) amends the information in our prospectus supplement dated May 4, 2023 (the “Prospectus Supplement”) relating to shares of |
|
| August 7, 2023 |
Exhibit 1.1 AMENDMENT NO. 1 TO SALES AGREEMENT August 7, 2023 This Amendment No. 1 (“Amendment No. 1”) amends that certain Sales Agreement, dated May 4, 2023 (the “Agreement”), by and between Avalo Therapeutics, Inc. (the “Company”) and Oppenheimer & Co. Inc., as agent (the “Agent”). Defined terms used herein and not otherwise defined shall have the meaning assigned to such terms in the Agreement. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-37590 AVALO THERAPEUTICS, INC. |
|
| August 3, 2023 |
Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates Exhibit 99.1 Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates •Announced AVTX-002 (quisovalimab) did not meet its primary endpoint in its Phase 2 PEAK Trial in non-eosinophilic asthma, however AVTX-002 significantly reduced serum LIGHT levels for study duration indicating strong target engagement •Disclosed cash of approximately $6.3 million as of June 30, 2023 WAY |
|
| July 21, 2023 |
avaloinvestordeckjuly202 1 © Copyright 2023. Avalo Therapeutics. All rights reserved. FOR DISCUSSION PURPOSES ONLY Avalo Therapeutics, Inc. July 2023 Corporate Presentation (AVTX) EX-99.1 2 © Copyright 2023. Avalo Therapeutics. All rights reserved. This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking stateme |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| July 21, 2023 |
EXHBIT-10.1 FORBEARANCE AGREEMENT This FORBEARANCE AGREEMENT (this “Agreement”) is made as of July 20, 2023, by and among (i) Avalo Therapeutics, Inc. (f/k/a Cerecor Inc.), a Delaware corporation (the “Borrower”), (ii) Horizon Credit II LLC, Horizon Funding Trust 2019-1, Horizon Funding I, LLC, and Powerscourt Investments XXV Trust, as lenders (collectively, the “Lenders”), and (iii) Horizon Techn |
|
| June 28, 2023 |
AVTX / Avalo Therapeutics Inc / ARMISTICE CAPITAL, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| June 26, 2023 |
Exhibit 99.1 Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma •AVTX-002 did not meet the primary endpoint measured by reduction in asthma related events compared to placebo, although positive trends were observed among a sub-population of patients with elevated baseline serum LIGHT levels •AVTX-002 significantly reduced serum |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| June 2, 2023 |
Exhibit 10.1 May 31, 2023 Avalo Therapeutics, Inc. 540 Gaither Road, Suite 400 Rockville, Maryland 20850 Re: Warrant Exchange Agreement Ladies and Gentlemen: This letter agreement (the “Agreement”) confirms the agreement of Avalo Therapeutics, Inc., a Delaware corporation (the “Company”), and the holders of the Common Stock listed on Schedule I attached hereto (the “Stockholders”), pursuant to whi |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission F |
|
| June 2, 2023 |
EX-4.1 2 ex-41venrockprexfundedwar.htm EX-4.1 Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: June 1, 2023 Avalo Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or |
|
| May 4, 2023 |
Exhibit 1.1 AVALO THERAPEUTICS, INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT May 4, 2023 Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Avalo Therapeutics, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Oppenheimer & Co. Inc. (the “Agent”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, f |
|
| May 4, 2023 |
As filed with the Securities and Exchange Commission on May 4, 2023 As filed with the Securities and Exchange Commission on May 4, 2023 Registration Statement No. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission Fi |
|
| May 4, 2023 |
EX-FILING FEES 2 ex-107sx8filingfeetable.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Avalo Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Share(3) Maximum Aggregate Offering Price( |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-37590 AVALO THERAPEUTICS, INC. |
|
| May 4, 2023 |
Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates Exhibit 99.1 Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates •Topline data expected in the second quarter of 2023 from the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA) •Disclosed cash of approximately $16.7 million as of March 31, 2023 WAYNE, PA AND ROCKVILLE, MD, May 4, 2023 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business upd |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission Fi |
|
| May 4, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-271225 PROSPECTUS SUPPLEMENT (To prospectus dated May 2, 2023) Up to $9,032,567 Common Stock We have entered into a sales agreement with Oppenheimer & Co. (the “Agent”) dated May 4, 2023, relating to the sale of shares of our common stock, $0.001 par value per share, offered by this prospectus supplement. In accordance with the terms of the sal |
|
| April 28, 2023 |
540 Gaither Road, Suite 400 Rockville, MD 20850 540 Gaither Road, Suite 400 Rockville, MD 20850 April 28, 2023 VIA EDGAR Division of Corporation Finance U. |
|
| April 25, 2023 |
As filed with the Securities and Exchange Commission on April 25, 2023 As filed with the Securities and Exchange Commission on April 25, 2023 Registration No. |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| April 12, 2023 |
As filed with the Securities and Exchange Commission on April 12, 2023 As filed with the Securities and Exchange Commission on April 12, 2023 Registration Statement No. |
|
| April 12, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Avalo Therapeutics, Inc. |
|
| April 12, 2023 |
Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.17 AVALO THERAPEUTICS, INC. and , as Trustee INDENTURE Dated as of [] [], 20[] TABLE OF CONTENTS Page Article 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1. DEFINITIONS. 1 1.2. RESERVED. 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT. 4 1.4. RULES OF CONSTRUCTION. 4 Article 2 THE SECURITIES 5 2.1. ISSUABLE IN SERIES. 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES. 5 |
|
| March 29, 2023 |
Avalo Reports 2022 Financial Results and Provides Business Updates Exhibit 99.1 Avalo Reports 2022 Financial Results and Provides Business Updates •Completed enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA); topline data expected in the second quarter of 2023 •Disclosed cash of approximately $13 million as of December 31, 2022, non-inclusive of the February 2023 public offering •Increased cash position with closing of public offer |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37590 |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| March 13, 2023 |
avaloinvestordeckmarch20 1 © Copyright 2023. Avalo Therapeutics. All rights reserved. FOR DISCUSSION PURPOSES ONLY Avalo Therapeutics, Inc. March 2023 Corporate Presentation (AVTX) EX-99.1 2 © Copyright 2023. Avalo Therapeutics. All rights reserved. This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statem |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| February 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Avalo Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 05338F108 (CUSIP Number) February 7, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu |
|
| February 14, 2023 |
AVTX / Avalo Therapeutics, Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236168d19sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* AVALO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 05338F108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the |
|
| February 14, 2023 |
SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, AMENDMENT #2 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Avalo Therapeutics, Inc. (Title |
|
| February 13, 2023 |
US05338F2074 / Avalo Therapeutics Inc / GREAT POINT PARTNERS LLC Passive Investment SC 13G 1 greatpoint-avtx020323.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AVALO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 05338F207 (CUSIP Number) February 3, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 9, 2023 |
AVTX / Avalo Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 3, 2023 |
Exhibit 99.2 Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants WAYNE, PA AND ROCKVILLE, MD, Feb. 02, 2023 — Avalo Therapeutics, Inc. (Nasdaq: AVTX) (Avalo) announced today the pricing of an underwritten public offering of 3,770,000 shares of its common stock and warrants to purchase up to an aggregate of 3,770,000 shares of common stock, at a pr |
|
| February 3, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissi |
|
| February 3, 2023 |
3,770,000 Shares of Common Stock Warrants to Purchase up to 3,770,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-254000 Prospectus Supplement (To prospectus dated March 19, 2021) 3,770,000 Shares of Common Stock Warrants to Purchase up to 3,770,000 Shares of Common Stock We are offering 3,770,000 shares of our common stock, par value $0.001 per share, and accompanying warrants to purchase up to 3,770,000 shares of our common stock (the “Warrants”) (and th |
|
| February 3, 2023 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT AVALO THERAPEUTICS, INC. Warrant Shares: [] Issue Date: February 7, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date set forth abo |
|
| February 3, 2023 |
Exhibit 99.1 Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants WAYNE, PA AND ROCKVILLE, MD, Feb. 02, 2023 — Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”) announced today that it has commenced a proposed underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. All of the shares and warrants in the prop |
|
| February 3, 2023 |
EX-1.1 2 ex-11underwritingagreement.htm EX-1.1 Exhibit 1.1 3,770,000 Shares 3,770,000 Warrants to Purchase 3,770,000 Shares Avalo Therapeutics, Inc. UNDERWRITING AGREEMENT February 2, 2023 SVB Securities LLC RBC Capital Markets, LLC As Representatives of the several Underwriters c/o SVB Securities LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o RBC Capital Markets, LLC 200 Vesey St |
|
| February 2, 2023 |
Subject to Completion, Dated February 2, 2023 Filed Pursuant to Rule 424(b)(5) Registration No. 333-254000 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying base prospectus are not an offer to sell these securities, a |
|
| January 17, 2023 |
Exhibit 99.1 Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma •Topline data expected in the second quarter of 2023 WAYNE, PA AND ROCKVILLE, MD, Jan. 17, 2023 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced that it completed enrollment of the 80 patients targeted for the Phase 2 PEAK Trial evaluating AVTX-002 |
|
| January 17, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2023 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissi |
|
| January 17, 2023 |
EX-99.2 3 ex-992avaloinvestordeck.htm EX-99.2 1 © Copyright 2023. Avalo Therapeutics. All rights reserved. FOR DISCUSSION PURPOSES ONLY Avalo Therapeutics, Inc. January 2023 Corporate Presentation (AVTX) EX-99.2 2 © Copyright 2023. Avalo Therapeutics. All rights reserved. This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commiss |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissi |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-37590 AVALO THERAPEUTICS, INC. |
|
| November 7, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Avalo Therapeutics, Inc. |
|
| November 7, 2022 |
Exhibit 10.3 PURCHASE AGREEMENT BY AND AMONG AVALO THERAPEUTICS, INC., AND ES THERAPEUTICS, LLC DATED AS OF NOVEMBER 4, 2022 TABLE OF CONTENTS Article 1 - PURCHASE, SALE AND ASSIGNMENT OF THE AGREEMENTS 2 Section 1.1 Purchase, Sale and Assignment; Waiver of Payment Rights 2 Section 1.2 Purchase PriceSection 2 Section 1.3 Sale 2 Article 2 - CLOSING 2 Section 2.1 Closing 2 Section 2.2 Payment of Pur |
|
| November 7, 2022 |
Exhibit 10.1 CERTAIN INFORMATION IDENTIFIED WITH THE MARK “(***)” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AGREEMENT This License Agreement (this “Agreement”), dated the 29th day of July, 2022 (the “Effective Date”), is by and between Apollo AP43 Limited, a company incorporated under |
|
| November 7, 2022 |
Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates Exhibit 99.1 Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates •Topline data expected in the first half of 2023 from the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA) •Entered into agreement to sell future economic rights to previously out-licensed assets in consideration for $5 million to be received upon closing •Progressed BTLA Agonist Fusion Pro |
|
| November 7, 2022 |
As filed with the Securities and Exchange Commission on November 7, 2022 As filed with the Securities and Exchange Commission on November 7, 2022 Registration Statement No. |
|
| August 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2022 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commissio |
|
| August 16, 2022 |
avtxirdeck08 1 © Copyright 2022. Avalo Therapeutics. All rights reserved. FOR DISCUSSION PURPOSES ONLY Avalo Therapeutics, Inc. August 2022 Corporate Presentation (AVTX) EX-99.1 2 © Copyright 2022. Avalo Therapeutics. All rights reserved. This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are st |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| August 11, 2022 |
Exhibit 10.1 WAIVER Reference is hereby made to the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the ?Certificate of Designation?), filed with the Delaware Secretary of State on April 27, 2017, by Avalo Therapeutics, Inc. (formerly known as Cerecor Inc.), a Delaware corporation (the ?Company?), and the Securities Purchase Agreement, bet |
|
| August 11, 2022 |
AVTX / Avalo Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| August 11, 2022 |
Avalo Therapeutics Announces Board Changes Exhibit 99.1 Avalo Therapeutics Announces Board Changes WAYNE, PA AND ROCKVILLE, MD, August 11, 2022 ? Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that on August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the ?Master Fund?), notified the Board of Directors (the ?Board?) of Avalo Therapeutics, I |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-37590 AVALO THERAPEUTICS, INC. |
|
| August 4, 2022 |
Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates Exhibit 99.1 Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates ?Transferred anti-IL 18 monoclonal antibody product (AVTX-007) to Apollo Therapeutics in July with the approximate $15 million of upfront payment received in August ?Dosed first patient in the Phase 2 PEAK Trial of its anti-LIGHT monoclonal antibody (AVTX-002) for the treatment of non-eosinophilic asthma |
|
| August 1, 2022 |
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics Exhibit 99.1 Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics ?Avalo to receive an approximately $15 million upfront payment, up to $74 million in milestone payments ?Apollo to lead continued clinical development of AVTX-007, currently in Phase 1b ROCKVILLE, MD, and CAMBRIDGE, United Kingdom, August 01, 2022 ? Avalo Therapeutics, Inc. (Nasdaq: AVTX) |
|
| August 1, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2022 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| July 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2022 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| July 7, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED OF AVALO THERAPEUTICS, INC. The undersigned, for purposes of amending the Amended and Restated Certificate of Incorporation, as amended (the ?Certificate?), of Avalo Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware |
|
| July 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2022 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission F |
|
| July 7, 2022 |
Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split Exhibit 99.1 Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split WAYNE, PA AND ROCKVILLE, MD, July 06, 2022 ? Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a one-for-twelve reverse stock split of the Company?s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time tomorrow, July 7, 2022. The Company?s common stock will trade on the Nasdaq Capital Mark |
|
| June 14, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission |
|
| May 24, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission F |
|
| May 24, 2022 |
EX-99.2 3 ex-992avaloinvestordeck.htm EX-99.2 1 © Copyright 2022. Avalo Therapeutics. All rights reserved. FOR DISCUSSION PURPOSES ONLY Avalo Therapeutics, Inc. May 2022 Corporate Presentation (AVTX) Exhibit 99.2 2 © Copyright 2022. Avalo Therapeutics. All rights reserved. This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995 |
|
| May 24, 2022 |
Exhibit 99.1 Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non- Eosinophilic Asthma (NEA) ?Topline results expected 4Q2022 WAYNE, Pa. AND ROCKVILLE, Md., May 18, 2022 ? Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced that the first patient has been dosed in the company?s Phase 2 PEAK (A Phase 2, Randomized, Double-Blind, Placebo-Cont |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Commission Fi |
|
| May 5, 2022 |
Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates Exhibit 99.1 Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates ?Reaffirms milestone timing for Phase 2 clinical trial of AVTX-002 in non-eosinophilic asthma (NEA) and pivotal trial of AVTX-803 in leukocyte adhesion deficiency type II (LAD II) ?Executed workforce reduction to align with previously announced pipeline prioritization ?Disclosed cash and cash equivalents of $ |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-37590 AVALO THERAPEUTICS, INC. |
